Clinical Trials Sponsored by pH Pharma

Total 8269 results

LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Atopic Dermatitis

United Kingdom
UCB Pharma

Completed

Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease

Parkinson's Disease

South Africa
UCB Pharma

Completed

Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures (PASS)

Epilepsies, Partial

France, Germany, United Kingdom, Spain, Netherlands
UCB Pharma

Completed

Prostaglandin E1 in Outpatients With Intermittent Claudication

Stage II Peripheral Arterial Occlusive Disease | Intermittent Claudication Fontaine Stage II PAOD

Germany
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

Parkinson's Disease
UCB Pharma

Completed

A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery (NEUPOS)

Parkinson's Disease

Germany
UCB Pharma

Completed

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

Parkinson's Disease
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms

Restless Legs Syndrome

Germany
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

Advanced Stage Parkinson's Disease

France, Italy, Poland, United Kingdom, Spain, Germany, South Africa, New Zealand, Czech Republic, Hungary, Australia, Austria, Israel, Sweden, Norway, Croatia, Finland
UCB Pharma

Completed

A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease

IDIOPATHIC PARKINSON'S DISEASE

Germany
UCB Pharma

Completed

Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects

Idiopathic Restless Legs Syndrome

Germany
UCB Pharma

Completed

Rotigotine Restless Legs Syndrome Dose Finding Trial

Idiopathic Restless Leg Syndrome

Germany
UCB Pharma

Completed

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathies

United States
UCB Pharma

Completed

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Epilepsies, Partial

United States
UCB Pharma

Completed

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

Epilepsy

United States, Poland, Mexico, Russian Federation
UCB Pharma

Completed

Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis

Allergic Rhinitis
Innate Pharma

Completed

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma (KIRMONO)

Smoldering Multiple Myeloma

United States
Innate Pharma

Completed

A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

Acute Myeloid Leukemia

France
Innate Pharma

Completed

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse (KIRIMID)

Patients With Multiple Myeloma Experiencing a | First or Second Relapse

United States
UCB Pharma

Completed

Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.

Allergy

France
UCB Pharma

Completed

Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

Allergies

United States
UCB Pharma

Completed

Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites

Rhinitis | Allergic | Perennial
UCB Pharma

Completed

Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects

Rhinitis, Allergic, Seasonal
UCB Pharma

Completed

Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis

Rhinitis, Allergic, Seasonal
UCB Pharma

Completed

Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures

Epilepsy
UCB Pharma

Completed

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Dyskinesia, Medication-induced

Belgium, Bulgaria
UCB Pharma

Completed

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

Idiopathic Parkinson Disease
UCB Pharma

Completed

Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy

Epilepsy
UCB Pharma

Completed

Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

Anxiety Disorders
LEO Pharma

Completed

A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris

Psoriasis Vulgaris

France
UCB Pharma

Completed

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Crohn's Disease
UCB Pharma

Completed

Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers

Bioavailability Study on Healthy Volunteers

France
UCB Pharma

Completed

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Crohn's Disease
UCB Pharma

Completed

A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis

Rheumatoid Arthritis
UCB Pharma

Completed

A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis

Multiple Sclerosis

United States
UCB Pharma

Completed

A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety

ANXIETY

United States
HRA Pharma

Completed

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

Contraception

United States, Sweden, United Kingdom
LEO Pharma

Completed

Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.

Multiple Myeloma
UCB Pharma

Completed

A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis

Diabetic Gastroparesis

United States
UCB Pharma

Terminated

Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, France, United Kingdom, Spain, Belgium, Netherlands, Canada, Brazil, Germany, Czech Republic, Italy
UCB Pharma

Completed

Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy

Epilepsy

United States
UCB Pharma

Withdrawn

Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy

Epilepsy
UCB Pharma

Completed

Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.

Epilepsy
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body

Healthy Volunteers

Germany
UCB Pharma

Completed

Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males

Healthy Volunteers

Netherlands
Sigmoid Pharma

Completed

Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)

Mild to Moderate Ulcerative Colitis

United Kingdom, Ireland
AM-Pharma

Completed

Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis

Sepsis | Multiple Organ Dysfunction Syndrome

Netherlands, Belgium
UCB Pharma

Withdrawn

Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.

Epilepsy

3

Subscribe